LLY Eli Lilly and Company | $786.45 +1.1% | +1.7%
 | Kisunla For the Treatment of Early Symptomatic Alzheimer's Disease | | 7/9/2025 - FDA approved Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a la… Full Summary |
EXAS Exact Sciences | $54.99 +2.7% | +0.7%
 | Oncodetect™ Molecular Residual Disease Test | | 7/9/2025 - Provided Update Exact Sciences Corp announced that its Oncodetect™ molecular residual disease (MRD) test has recei… Full Summary |
KRYS Krystal Biotech | $148.91 +3.9% | +9.4%
 | KB801 For the Treatment of Neurotrophic Keratitis | Phase 1/2 | 7/9/2025 - Dose Update Krystal Biotech, Inc announced that the first patient has been dosed in its Phase 1/2 clinical trial… Full Summary |
RZLT Rezolute | $5.35 +7.5% | +24.0%
 | Ersodetug For Hypoglycemia Due to Congenital Hyperinsulinism | Phase 3 | 7/9/2025 - Abstract Rezolute, Inc announced that the abstract titled "Preliminary Patient Demographics And Baseline Char… Full Summary |
BCTX Briacell Therap | $2.14 -26.6% | -38.6%
 | Bria-OTS In metastatic breast cancer | | 7/9/2025 - Provided Update BriaCell Therapeutics Corp announced the sustained complete resolution of lung metastasis in a patie… Full Summary |
ALT Altimmune | $4.78 +4.3% | -19.7%
 | pemvidutide for the treatment of obesity and MASH | Phase 2 | 7/9/2025 - Enrollment Update Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase 2 trial evalua… Full Summary |
ARTL Artelo Biosciences | $18.88 +18.8% | +183.5%
 | ART26.12 For the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy. | | 7/9/2025 - Data Presentation Artelo Biosciences, announced the presentation of preclinical data in an osteaoarthritis (OA) pain … Full Summary |
BIVI BioVie | $8.16 -3.7% | -27.2%
 | Bezisterim For Parkinson's Disease Patients | | 7/9/2025 - Provided Update BioVie Inc. presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th Worl… Full Summary |
EOLS Evolus | $9.81 +5.9% | +1.7%
 | Nuceiva® For the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2. | | 7/9/2025 - Provided Update Evolus, Inc announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinu… Full Summary |
BHC Bausch Health Cos | $6.66 -0.7% | +36.4%
 | CABTREO For the Treatment of Acne Vulgaris | | 7/9/2025 - Provided Update Bausch Health, Canada Inc announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl … Full Summary |
KALA KALA BIO | $5.71 +10.7% | +38.9%
 | KPI-012 Clinical diagnosis of PCED | | 7/9/2025 - Enrollment Completion KALA BIO, Inc. announced the completion of patient enrollment in the CHASE (Corneal Healing After SE… Full Summary |
KALA KALA BIO | $5.71 +10.7% | +38.9%
 | KPI-012 Clinical diagnosis of PCED | Target date: 2025-Q3 | 7/9/2025 - Top-line results KALA BIO, Inc. announced that Topline results from the CHASE trial expected by end of Q3 2025 -- Full Summary |
RYTM Rhythm Pharmaceuticals | $88.37 +35.7% | +32.4%
 | bivamelagon In patients with acquired hypothalamic obesity. | Phase 2 | 7/9/2025 - Top-line results Rhythm Pharmaceuticals, Inc. announced positive topline results from its Phase 2 trial evaluating bi… Full Summary |
BHC Bausch Health Cos | $6.66 -0.7% | +36.4%
 | PrCABTREOTM For Treatment Of Acne Vulgaris | | 7/9/2025 - Provided Update Bausch Health, Canada Inc., part of Bausch Health Companies Inc. announced that PrCABTREOTM (clinda… Full Summary |
BNTC Benitec Biopharma | $13.14 +4.1% | -18.8%
 | BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 7/9/2025 - Enrollment Update Benitec Biopharma Inc. announced the recommendation of the independent Data Safety Monitoring Board… Full Summary |
EVOK Evoke Pharma | $7.18 +169.8% | +142.9%
 | GIMOTI (metoclopramide) nasal spray Acute and recurrent diabetic gastroparesis | | 7/9/2025 - Notice of Allowance Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the United States Pat… Full Summary |
ELAN Elanco Animal Health | $14.84 +0.6% | +6.4%
 | TruCan™ Ultra Canine Influenza Vaccine | | 7/9/2025 - Approved Elanco Animal Health announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra … Full Summary |
ASBP Aspire Biopharma | $0.34 +7.6% | -14.7%
 | BUZZ BOMB New Sublingual Pre-Workout Supplement | | 7/9/2025 - Positive Feedback Aspire Biopharma Holdings, Inc. announced positive initial consumer feedback from the Company's samp… Full Summary |
MTVA MetaVia | $0.69 +8.5% | -3.7%
 | DA-1726 For The Treatment Of Obesity | Phase 1 | 7/9/2025 - Dosing Update MetaVia Inc. announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) coho… Full Summary |
MTVA MetaVia | $0.69 +8.5% | -3.7%
 | DA-1726 For The Treatment Of Obesity | Target date: 2025-Q4 | 7/9/2025 - Top-line data MetaVia Inc. announced that Top-Line Data Expected in the Fourth Quarter of 2025 Full Summary |
CNTB Connect Biopharma | $1.10 -3.2% | +40.7%
 | Rademikibart For Moderate-To-Severe Atopic Dermatitis | NDA | 7/9/2025 - NDA Filing Connect Biopharma Holdings Limited announced that the Company's collaborator and exclusive licensee… Full Summary |
MRK Merck & Co., Inc. | $83.96 +3.2% | +5.9%
 | MK-8527 novel nucleoside reverse transcriptase translocation inhibitor | | 7/8/2025 - New Data Merck announced that new data from its research pipeline for HIV prevention and treatment will be p… Full Summary |
ETON Eton Pharmaceuticals | $15.97 +1.1% | +0.8%
 | ET-600 For the treatment of an endocrinology | NDA | 7/8/2025 - FDA review Eton Pharmaceuticals, Inc announced the Company's New Drug Application (NDA) for ET-600, a propriet… Full Summary |
ETON Eton Pharmaceuticals | $15.97 +1.1% | +0.8%
 | ET-600 For the treatment of an endocrinology | NDA Target date: 2026-02-25 | 7/8/2025 - PDUFA Date Eton Pharmaceuticals, Inc announced that NDA has been assigned a Prescription Drug User Fee Act (… Full Summary |
LRMR Larimar Therapeutics | $3.49 +5.0% | +31.0%
 | nomlabofusp For Friedreich's Ataxia | | 7/8/2025 - Publication Larimar Therapeutics, announced the publication of two peer-reviewed articles highlighting nonclin… Full Summary |
EPRX Eupraxia Pharmaceuticals | $5.54 -1.0% | +39.4%
 | EP-104GI For Treatment of Eosinophilic Esophagitis | Phase 2b | 7/8/2025 - Dose Update Eupraxia Pharmaceuticals Inc. announced the first patient dosed in the Phase 2b randomized, placebo-… Full Summary |
UPB Upstream Bio | $11.48 +5.4% | +1.7%
 | Verekitug In Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | 7/8/2025 - Dose Update Upstream Bio, Inc. announced that the first patient has been dosed in the Company's Phase 2 clinica… Full Summary |
PSTV Plus Therapeutics | $0.36 +7.4% | +2.8%
 | REYOBIQ™ For Patients with Leptomeningeal Metastases | | 7/8/2025 - Provided Update Plus Therapeutics, Inc. announced the treatment of its initial patients in the Company's ReSPECT-LM… Full Summary |
ARWR Arrowhead Pharmaceuticals | $18.81 +7.2% | +13.5%
 | Zodasiran For the Treatment of Homozygous Familial Hypercholesterolemia | Phase 3 | 7/8/2025 - Dose Update Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first subject in the YOSEMITE Phase … Full Summary |
BCLI Brainstorm Cell Therapeutics | $1.28 -2.7% | +2.8%
 | NurOwn Progressive Multiple Sclerosis (MS) | | 7/8/2025 - Provided Update BrainStorm Cell Therapeutics Inc today acknowledged that the U.S. Food and Drug Administration's (F… Full Summary |
ITCI Intra-Cellular Therapies | $131.87
| | CAPLYTA (Lumateperone) Depressive Episodes associated with Bipolar | supplemental New Drug Application (sNDA) | 7/8/2025 - sNDA Filing Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.… Full Summary |
JNJ Johnson & Johnson | $155.65 -0.1% | +0.3%
 | CAPLYTA (Lumateperone) Depressive Episodes associated with Bipolar | supplemental New Drug Application (sNDA) | 7/8/2025 - sNDA Filing Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S.… Full Summary |
ONCY Oncolytics Biotech | $1.21 -3.5% | +171.1%
 | Pelareorep In Breast Cancer | | 7/8/2025 - Clinical Data Oncolytics Biotech® Inc announced a strategic update highlighting its compelling clinical data from… Full Summary |
MAT Mattel | $20.14 +0.2% | +5.6%
 | Barbie type 1 diabetes (T1D) | | 7/8/2025 - Provided Update Mattel, Inc announced that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D). Full Summary |
RYTM Rhythm Pharmaceuticals | $88.37 +35.7% | +32.4%
 | bivamelagon In patients with acquired hypothalamic obesity. | Phase 2 | 7/8/2025 - Provided Update Rhythm Pharmaceuticals, Inc announced the Company will hold a conference call and webcast on Wednes… Full Summary |
SLDB Solid Biosciences | $5.69 +8.5% | +23.1%
 | SGT-501 For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) | IND | 7/8/2025 - FDA Approval Solid Biosciences Inc. announced approval of its Investigational New Drug (IND) application by the … Full Summary |
SLDB Solid Biosciences | $5.69 +8.5% | +23.1%
 | SGT-501 For the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) | Phase 1b | 7/8/2025 - Clinical Trial Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - Full Summary |
KALV KalVista Pharmaceuticals | $15.85 +6.0% | +7.4%
 | sebetralstat Therapy for hereditary angioedema (HAE). | | 7/7/2025 - FDA Approval KalVista Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approv… Full Summary |
TNXP Tonix Pharmaceuticals | $37.81 +6.3% | -3.6%
 | TNX-801 Potential Vaccine to Prevent Mpox and Smallpox | | 7/7/2025 - Data Presentation Tonix Pharmaceuticals announced that Sina Bavari, PhD, Executive Vice President of Infectious Diseas… Full Summary |
NTRA Natera | $163.15 +2.9% | -0.6%
 | Latitude™ For Colorectal Cancer | | 7/7/2025 - Data Natera, Inc announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD as… Full Summary |
BSX Boston Scientific | $102.83 +0.4% | +2.8%
 | FARAPULSE™ A nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (AF). | | 7/7/2025 - FDA Approval Boston Scientific Corporation announced that it has received U.S. Food and Drug Administration (FDA… Full Summary |
BYSI BeyondSpring | $2.29 +3.4% | +3.4%
 | plinabulin Patients with non-small cell lung cancer | | 7/7/2025 - Publication BeyondSpring Inc. announced publication of a human clinical study in Med (Cell Press) demonstrating… Full Summary |
COGT Cogent Biosciences | $10.61 +8.4% | +53.7%
 | bezuclastinib In patients with non-advanced systemic mastocytosis | | 7/7/2025 - Top-line results Cogent Biosciences, Inc. announced positive top-line results from the registration-directed Part 2 … Full Summary |
OGN Organon & Co. | $10.03 +0.8% | +2.7%
 | VTAMA (tapinarof) cream Plaque psoriasis | | 7/7/2025 - Recommendation Organon announced that VTAMA® (tapinarof) cream, 1%,was granted a strong recommendation by the Ameri… Full Summary |
JSPR Jasper Therapeutics | $3.74 +23.8% | -37.1%
 | Briquilimab To address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) | Phase 1b/2a | 7/7/2025 - Updated data Jasper Therapeutics is reporting updated data from Company's BEACON Phase 1b/2a study of subcutaneo… Full Summary |
ARTL Artelo Biosciences | $18.88 +18.8% | +183.5%
 | ART12.11 For overcoming problematic drug properties which allows for precise control over purity, potency, and consistency. | | 7/7/2025 - Data Presentation Artelo Biosciences announced the presentation of compelling new preclinical data on its Cannabidiol… Full Summary |
URGN Urogen Pharma | $13.83 +0.9% | +97.0%
 | UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | 7/7/2025 - Enrollment Completion UroGen Pharma Ltd. announced that it has completed patient enrollment in its Phase 3 UTOPIA clinica… Full Summary |
DNLI Denali Therapeutics | $15.14 +5.7% | +3.4%
 | tividenofusp For the treatment of Hunter syndrome (MPS II) | BLA | 7/7/2025 - FDA review Denali Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for… Full Summary |
DNLI Denali Therapeutics | $15.14 +5.7% | +3.4%
 | tividenofusp For the treatment of Hunter syndrome (MPS II) | BLA Target date: 2026-01-05 | 7/7/2025 - PDUFA Date Denali Therapeutics Inc. announced that The FDA granted the BLA Priority Review with a Prescription… Full Summary |
KALA KALA BIO | $5.71 +10.7% | +38.9%
 | KPI-012 Clinical diagnosis of PCED | | 7/7/2025 - Provided Update KALA BIO, Inc. announced that the Company will host a webcast event with Key Opinion Leaders (KOLs… Full Summary |
AGEN Agenus | $5.28 +8.5% | -5.0%
 | BOT/BAL In Metastatic MSS Colorectal Cancer | Phase 3 | 7/7/2025 - Provided Update Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA)… Full Summary |
MBIO Mustang Bio | $3.17 +19.0% | +145.3%
 | MB-101 Leptomeningeal brain tumors | Orphan Drug | 7/7/2025 - Designation Grant Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr… Full Summary |
FBIO Fortress Biotech | $1.99 +2.8% | -6.8%
 | MB-101 Leptomeningeal brain tumors | Orphan Drug | 7/7/2025 - Designation Grant Mustang Bio, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Dr… Full Summary |
IINN Inspira Technologies OXY B.H.N. | $1.45 -3.0% | +97.9%
 | ART100 Cardio-Pulmonary Bypass Device | | 7/7/2025 - Provided Update Inspira™ Technologies OXY B.H.N. Ltd. announced that it is engaged in high-level talks with a gover… Full Summary |
IMMX Immix Biopharma | $2.72 +2.3% | +16.2%
 | NXC-201 NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. | | 7/7/2025 - Provided Update Immix Biopharma, Inc. announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/ref… Full Summary |
ASND Ascendis Pharma A/S | $179.30 +6.6% | +3.5%
 | TransCon PTH Adult Hypoparathyroidism | | 7/7/2025 - Oral presentation Ascendis Pharma A/S announced two oral presentations at ENDO 2025, the annual meeting of the Endoc… Full Summary |
APGE Apogee Therapeutics | $37.97 +4.3% | -5.4%
 | APG777 For the Treatment for Atopic Dermatitis and Other Inflammatory Diseases | Phase 2 | 7/6/2025 - Data Apogee Therapeutics, Inc announced it will report Part A 16-week data from the Phase 2 APEX trial o… Full Summary |
NVS Novartis | $122.83 +0.9% | +4.1%
 | secukinumab In adults with newly diagnosed or relapsing giant cell arteritis (GCA). | Phase 3 | 7/3/2025 - Top-line results Novartis announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinu… Full Summary |
BCAB BioAtla | $0.41 +4.4% | -20.2%
 | BA3182 In Patients with Treatment Refractory Metastatic Adenocarcinoma | | 7/3/2025 - Data Presentation BioAtla, Inc today presented first-in-human data in a poster titled "Preliminary Results from a Fir… Full Summary |
MIRA MIRA Pharmaceuticals | $1.14 +0.9% | -11.6%
 | MIRA-55 Potential treatment for anxiety and cognitive decline. | | 7/3/2025 - Preclinical Data MIRA Pharmaceuticals, Inc. announced positive preclinical data demonstrating that Mira-55, the Com… Full Summary |
VRTX Vertex Pharmaceuticals | $475.56 +2.0% | +6.6%
 | exagamglogene autotemcel For severe sickle cell disease | | 7/3/2025 - Positive Data Vertex Pharmaceuticals announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel… Full Summary |
BLTE Belite Bio | $63.44 +5.5% | +3.3%
 | Tinlarebant In Stargardt Disease | Phase 3 | 7/2/2025 - Enrollment Update Belite Bio, Inc announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phas… Full Summary |
TIL Instil Bio | $25.79 +10.1% | -26.5%
 | AXN-2510 In Relapsed/Refractory Solid Tumors | IND | 7/2/2025 - FDA Clearance Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for AXN-25… Full Summary |
MRK Merck & Co., Inc. | $83.96 +3.2% | +5.9%
 | sotatercept-csrk In adults with pulmonary arterial hypertension | BLA Priority Review | 7/2/2025 - FDA GRANT Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority r… Full Summary |
MRK Merck & Co., Inc. | $83.96 +3.2% | +5.9%
 | sotatercept-csrk In adults with pulmonary arterial hypertension | BLA Priority Review Target date: 2025-10-25 | 7/2/2025 - PDUFA Date Merck announced that The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date… Full Summary |
CTSO Cytosorbents | $1.08 +2.9% | | DrugSorb-ATR Antithrombotic Removal System | | 7/2/2025 - Regulatory Update CytoSorbents Corporation today provided a regulatory update on its marketing applications for DrugS… Full Summary |
TNXP Tonix Pharmaceuticals | $37.81 +6.3% | -3.6%
 | TNX-1700 Recombinant human TFF2-human serum albumin or HSA) for the treatment of colon and gastric cancers. | | 7/2/2025 - Publication Tonix Pharmaceuticals Holding Corp announced the publication of a paper entitled, "A CXCR4 Partial… Full Summary |
OGN Organon & Co. | $10.03 +0.8% | +2.7%
 | OG-6219 In Patients with Endometriosis-Related Pain | Phase 2 | 7/2/2025 - Endpoint Missed Organon announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational cand… Full Summary |
VYNE VYNE Therapeutics | $1.45 +4.7% | +50.7%
 | VYN202 A Novel BD2-Selective BET Inhibitor | Phase 1b | 7/2/2025 - Provided Update VYNE Therapeutics Inc today provided a program update for VYN202 following the clinical hold issue… Full Summary |
CERS Cerus | $1.48 +1.0% | +0.3%
 | INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells | | 7/2/2025 - Regulatory Update Cerus Corporation announced a European regulatory update on the INTERCEPT RBC program. Full Summary |
IINN Inspira Technologies OXY B.H.N. | $1.45 -3.0% | +97.9%
 | ART100 Cardio-Pulmonary Bypass Device | | 7/2/2025 - Provided Update Inspira™ Technologies OXY B.H.N. Ltd. announced it has secured a binding $22.5 million purchase or… Full Summary |
REGN Regeneron Pharmaceuticals | $547.06 -0.1% | +5.7%
 | linvoseltamab-gcpt For Treatment of Relapsed or Refractory Multiple Myeloma | | 7/2/2025 - FDA GRANT Regeneron Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has grant… Full Summary |
IMAB I-Mab | $2.31 +5.0% | -17.5%
 | Givastomig In patients with advanced cancers | Phase 1b | 7/2/2025 - Positive Data I-Mab announced the presentation of positive Phase 1b combination data for givastomig, in combinati… Full Summary |
IVA Inventiva | $3.40 -1.8% | -6.3%
 | Lanifibranor Nonalcoholic steatohepatitis (NASH) | Phase 2b | 7/2/2025 - Publication Inventiva announces the publication in Journal of Hepatology Reports, a peer-reviewed, scientific jo… Full Summary |
FDMT 4D Molecular Therapeutics | $4.46 +5.7% | -6.9%
 | 4D-150 Intravitreal vector, R100, and a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi. | Phase 3 | 7/2/2025 - Provided Update 4D Molecular Therapeutics announced the acceleration of the 4D-150 4FRONT Phase 3 program in wet ag… Full Summary |
ATAI atai Life Sciences | $2.71 +2.9% | +18.6%
 | BPL-003 In Patients With Treatment Resistant Depression | Phase 2b | 7/1/2025 - Top-line results atai Life Sciences and Beckley Psytech Limited jointly announced positive topline results from the… Full Summary |
NVCR NovoCure | $18.10 +3.4% | +7.1%
 | Tumor Treating Fields - PANOVA-3 Locally advanced pancreatic cancer | Phase 3 | 7/1/2025 - Results Novocure announced that it will present the final secondary endpoint results from the Phase 3 PANOV… Full Summary |
BTAI BioXcel Therapeutics | $2.00 -0.7% | +1.8%
 | BXCL501 (SERENITY) Schizophrenia and bipolar disorders | | 7/1/2025 - Recommendation BioXcel Therapeutics announced the second positive recommendation by an independent Data Safety Moni… Full Summary |
BTAI BioXcel Therapeutics | $2.00 -0.7% | +1.8%
 | BXCL501 (SERENITY) Schizophrenia and bipolar disorders | Target date: 2025-Q3 | 7/1/2025 - Top-line data BioXcel Therapeutics, Inc announced that Topline data expected in Q3 2025. Full Summary |
ADPT Adaptive Biotechnologies | $12.00 +2.2% | +14.8%
 | clonoSEQ Treatments for patients with lymphoid malignancies. | | 7/1/2025 - Provided Update Adaptive Biotechnologies announced the integration of Adaptive's clonoSEQ® test for measurable resi… Full Summary |
SLNO Soleno Therapeutics | $88.72 +4.1% | +14.1%
 | VYKAT XR To Treat Hyperphagia in Prader-Willi Syndrome | | 7/1/2025 - Abstract Presentation Soleno Therapeutics, announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) ex… Full Summary |
JAZZ Jazz Pharmaceuticals | $110.73 +1.5% | -1.0%
 | Ziihera For the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) | European Commission Conditional Marketing Authorization | 7/1/2025 - Marketing authorization Jazz Pharmaceuticals plc announced that the European Commission (EC) has granted conditional market… Full Summary |
MBIO Mustang Bio | $3.17 +19.0% | +145.3%
 | MB-101 Leptomeningeal brain tumors | Orphan Drug | 7/1/2025 - Designation Grant Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma Full Summary |
FBIO Fortress Biotech | $1.99 +2.8% | -6.8%
 | MB-101 Leptomeningeal brain tumors | Orphan Drug | 7/1/2025 - Designation Grant Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma Full Summary |
BTAI BioXcel Therapeutics | $2.00 -0.7% | +1.8%
 | BXCL501 (SERENITY) Schizophrenia and bipolar disorders | | 7/1/2025 - Recommendation BioXcel Therapeutics, Inc. announced the second positive recommendation by an independent Data Safe… Full Summary |
CUE Cue Biopharma | $0.79 +7.5% | +23.7%
 | CUE-101 HPV+ recurrent/metastatic head and neck cancer | | 7/1/2025 - Provided Update Cue Biopharma, provided an update on its most advanced clinical stage asset, CUE-101, representative… Full Summary |
ARGX argenex | $554.95 +3.0% | -4.9%
 | ARGX-119 In Congenital Myasthenic Syndromes | Phase 1b | 6/30/2025 - Provided Update argenx SE announced its plan to advance the clinical development of ARGX-119, a first-in-class agon… Full Summary |
AZN AstraZeneca | $70.60 +0.8% | -3.3%
 | TAGRISSO® (osimertinib) Third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. | NDA | 6/30/2025 - Approved HUTCHMED (China) Limited announces that the New Drug Application ("NDA") for the combination of ORP… Full Summary |
RCKT Rocket Pharmaceuticals | $3.19 +7.6% | +5.5%
 | RP-A701 For the Treatment of BAG3-associated Dilated Cardiomyopathy | IND | 6/30/2025 - FDA Clearance Rocket Pharmaceuticals, Inc. announced that it has received clearance from the U.S. Food and Drug Ad… Full Summary |
SAVA Cassava Sciences | $2.22 +6.5% | +3.0%
 | Simufilam Alzheimer's Disease | | 6/30/2025 - Poster Presentation Cassava Sciences, Inc. announced that the Company presented a poster at the TSC International Resea… Full Summary |
AVDL Avadel Pharmaceuticals | $9.77 +8.0% | -3.0%
 | LUMRYZ (sodium oxybate) Extended-release sodium oxybate medication | | 6/30/2025 - Regulatory Update Avadel Pharmaceuticals plc announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for t… Full Summary |
MRNA Moderna | $32.64 +0.3% | +16.0%
 | mRNA-1010 Quadrivalent Seasonal Flu | Phase 3 | 6/30/2025 - Positive Results Moderna, Inc. announced positive results from a Phase 3 efficacy study (P304) evaluating the relativ… Full Summary |
CELC Celcuity | $13.88 +3.6% | +7.5%
 | Gedatolisib HR+ / HER2- Metastatic Breast Cancer | | 6/30/2025 - Clinical Data Celcuity Inc. announced preliminary clinical data for gedatolisib in two early phase clinical trials… Full Summary |
PSTV Plus Therapeutics | $0.36 +7.4% | +2.8%
 | REYOBIQ™ For Patients with Leptomeningeal Metastases | | 6/30/2025 - Trial Initiation Plus Therapeutics, Inc announces the initiation of the ReSPECT-LM dose optimization trial for REYOBI… Full Summary |
INMB INmune Bio | $2.48 +7.6% | -67.6%
 | XPro For treatment of Alzheimer's Disease | | 6/30/2025 - Findings Update INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease Full Summary |
BIIB Biogen | $133.66 -0.6% | -0.4%
 | Felzartamab For the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients | | 6/30/2025 - Dosing Update Biogen Inc. announced the initiation of dosing in the global clinical study, PROMINENT. Full Summary |
ARTL Artelo Biosciences | $18.88 +18.8% | +183.5%
 | ART26.12 For the prevention of chemotherapy-induced peripheral neuropathy, a debilitating and often treatment-altering side effect of cancer therapy. | | 6/30/2025 - Results Artelo Biosciences, announced favorable results from its first-in-human study evaluating ART26.12, … Full Summary |
ASMB Assembly Biosciences | $18.46 +2.0% | +14.8%
 | ABI-1179 For Recurrent Genital Herpes | Phase 1 | 6/30/2025 - Dosing Update Assembly Biosciences, Inc. announced that the first participant has been dosed in the Phase 1b porti… Full Summary |
CMMB Chemomab Therapeutics | $1.19 +2.6% | -9.8%
 | nebokitug In Sclerosing Cholangitis | Phase 2 | 6/30/2025 - Data Presentation Chemomab Therapeutics, Ltd announced that data from the company's Phase 2 SPRING trial of nebokitug… Full Summary |
TPST Tempest Therapeutics | $7.52 +1.1% | -16.0%
 | TPST-1120 First-Line Regimen for Hepatocellular Carcinoma | | 6/30/2025 - Received Approval Tempest Therapeutics, Inc. announced that the company received approval from the National Medical P… Full Summary |